| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A composite burden score for severe asthma
|
Bousquet, Jean
|
|
|
13 |
1 |
p. 3-5
|
artikel
|
| 2 |
A new era in the treatment of acute exacerbations of asthma and COPD
|
Leung, Clarus
|
|
|
13 |
1 |
p. 6-8
|
artikel
|
| 3 |
An international consensus on the use of asthma biologics in pregnancy
|
Naftel, Jennifer
|
|
|
13 |
1 |
p. 80-91
|
artikel
|
| 4 |
A response to therapy for COPD with dupilumab
|
Bhatt, Surya P
|
|
|
13 |
1 |
p. e3
|
artikel
|
| 5 |
Asthma remission: a call for a globally standardised definition
|
Lommatzsch, Marek
|
|
|
13 |
1 |
p. 2-3
|
artikel
|
| 6 |
Caring for our interlocutors on the threshold of life and death
|
Zegarra Chiappori, Magdalena
|
|
|
13 |
1 |
p. 18-20
|
artikel
|
| 7 |
Clinical remission attainment, definitions, and correlates among patients with severe asthma treated with biologics: a systematic review and meta-analysis
|
Shackleford, Amy
|
|
|
13 |
1 |
p. 23-34
|
artikel
|
| 8 |
Development of an asthma health-care burden score as a measure of severity and predictor of remission in SARP III and U-BIOPRED: results from two major longitudinal asthma cohorts
|
Zein, Joe G
|
|
|
13 |
1 |
p. 35-46
|
artikel
|
| 9 |
Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trial
|
Singh, Dave
|
|
|
13 |
1 |
p. 47-58
|
artikel
|
| 10 |
Empirical antibiotic therapy for sepsis: save the anaerobic microbiota
|
Kullberg, Robert F J
|
|
|
13 |
1 |
p. 92-100
|
artikel
|
| 11 |
Evaluating tezepelumab for COPD: a missed target or unmet potential?
|
Cazzola, Mario
|
|
|
13 |
1 |
p. 5-6
|
artikel
|
| 12 |
Global, regional, and national burden of pulmonary arterial hypertension, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
|
|
|
|
13 |
1 |
p. 69-79
|
artikel
|
| 13 |
GOLD COPD report: 2025 update
|
Venkatesan, Priya
|
|
|
13 |
1 |
p. e7-e8
|
artikel
|
| 14 |
Health care in Ukraine: If everybody leaves, who will stay?
|
Burki, Talha
|
|
|
13 |
1 |
p. e6
|
artikel
|
| 15 |
Incorrect interpretation of the role of COVID-19 vaccination boosters in saving lives
|
De Bie, Tijl
|
|
|
13 |
1 |
p. e4
|
artikel
|
| 16 |
Incorrect interpretation of the role of COVID-19 vaccination boosters in saving lives – Authors' reply
|
Meslé, Margaux M I
|
|
|
13 |
1 |
p. e5
|
artikel
|
| 17 |
Lifetime non-smoker survives stage IV lung cancer four times
|
Kirby, Tony
|
|
|
13 |
1 |
p. 20-22
|
artikel
|
| 18 |
Managing tuberculosis before the onset of symptoms
|
Falzon, Dennis
|
|
|
13 |
1 |
p. 14-15
|
artikel
|
| 19 |
Navigating uncertainty: asthma biologics during pregnancy
|
Howell, Imran
|
|
|
13 |
1 |
p. 10-11
|
artikel
|
| 20 |
The global burden of pulmonary arterial hypertension: profound but improving?
|
Newman, Joseph
|
|
|
13 |
1 |
p. 8-9
|
artikel
|
| 21 |
The UK Tobacco and Vapes Bill: a historic opportunity
|
The Lancet Respiratory Medicine,
|
|
|
13 |
1 |
p. 1
|
artikel
|
| 22 |
Thoracentesis: an old story and some new sources
|
Drouin, Emmanuel
|
|
|
13 |
1 |
p. 16-18
|
artikel
|
| 23 |
Top ten research priorities for breathlessness research: UK James Lind Alliance priority setting partnership
|
Evans, Rachael A
|
|
|
13 |
1 |
p. e1-e2
|
artikel
|
| 24 |
Treating eosinophilic exacerbations of asthma and COPD with benralizumab (ABRA): a double-blind, double-dummy, active placebo-controlled randomised trial
|
Ramakrishnan, Sanjay
|
|
|
13 |
1 |
p. 59-68
|
artikel
|
| 25 |
5 years of COVID-19: equity must lead the next pandemic response in a fractured multipolar world
|
Hui, David S C
|
|
|
13 |
1 |
p. 11-14
|
artikel
|
Tijdschrift beschrijving